🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524910-28-00
Authorised Phase I

A bioequivalence study comparing Empagliflozin 25 mg film-coated tablets, VIANEX S.A., Greece versus Jardiance 25 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.

2025-524910-28-00 · tracked via the Priya Life Science EU tracker
Sponsor
Vianex S.A.
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
18/02/2026
Enrollment target
36
Sites
Czechia

Condition studied

none - healthy volunteers

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524910-28-00 on CTIS ↗ ← All trials in the EU